InterVenn

What InterVenn does

InterVenn Biosciences (legally Venn Biosciences Corporation) operates a proprietary AI-powered glycoproteomics platform that combines high-resolution mass spectrometry with custom neural networks to decode complex glycan signatures associated with disease. The company's core engine, branded GlycoVision, is trained on what InterVenn describes as the largest clinically annotated glycoproteomic dataset in the world, and is used to automate glycopeptide identification, scoring, and biomarker discovery across oncology, autoimmune, and infectious disease indications. Layered on top of GlycoVision is the GlycoKnow™ diagnostic franchise, beginning with GlycoKnow™ Ovarian, a CLIA-validated laboratory-developed blood test that assesses malignancy risk in women with documented adnexal masses prior to surgery; the test is performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory in South San Francisco.

The company makes money on three axes. First, it sells GlycoKnow™ Ovarian as an LDT on a quote-based, pay-as-you-go basis to clinicians and women's-health practices through select clinical partners and early access programs; the test is not currently eligible for insurance reimbursement. Second, it offers collaborative biomarker discovery and validation services to biopharma and academic research partners using the GlycoVision engine, executed on serum or plasma samples. Third, it leverages a multi-year distribution partnership with Aranscia — embedding the test into Spesana, 2bPrecise, and AccessDx Laboratory platforms — to reach health systems, oncology, and women's health providers at scale.

The company is privately held and venture-backed, having raised approximately $244M across four rounds including a $201M Series C led by SoftBank Group in August 2021. Leadership is headed by CEO Andrew Quong, with COO David A. King (ex-Standard Biotools), CLO Nicholas S. Khadder, and scientific advisors Carolyn Bertozzi (Stanford, HHMI, 2022 Nobel laureate) and Carlito B. Lebrilla (UC Davis). InterVenn has 51-100 employees, operates primarily from South San Francisco with a London investor presence, and is currently commercializing through a sales-led GTM that combines direct clinical-lab sales, channel partnerships, and event-driven demand generation (e.g., SITC 2026).

Name

InterVenn

Legal name

Venn Biosciences Corporation

Website

https://intervenn.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

InterVenn Biosciences operates an AI-powered glycoproteomics platform that combines proprietary neural networks with mass spectrometry to enable blood-based liquid biopsy diagnostics and biomarker discovery, primarily serving clinicians, women's-health practices, health systems, and biopharma research collaborators.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

Keywords

• Glycoproteomic diagnostics
• Liquid biopsy testing
• AI biomarker discovery
• Ovarian cancer screening
• Clinical mass spectrometry

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. GlycoKnow™ Ovarian LDT Sales: Revenue generated by selling GlycoKnow™ Ovarian as a laboratory-developed test (LDT) through select clinical partners and early access programs. Specimen-based clinical testing performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory. Test is not currently eligible for insurance reimbursement (per stated intended use disclosure).
2. Discovery & Validation Services via GlycoVision: Service offering for research partners to outsource discovery or validation cohorts using the GlycoVision engine, including study design, sample processing (serum/plasma), and data interpretation end-to-end.
3. Clinical Workflow Integration & Commercial Partnerships: Multi-year partnership with Aranscia to commercialize GlycoKnow™ Ovarian via Aranscia's Spesana, 2bPrecise, and AccessDx Laboratory platforms — embedding InterVenn's liquid biopsy into health system clinical workflows.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

InterVenn Biosciences develops and commercializes an AI-powered glycoproteomics platform (GlycoVision) that combines high-resolution mass spectrometry with proprietary neural networks to decode the glycoproteome for biomarker discovery and clinical diagnostics. Its flagship commercial product is GlycoKnow™ Ovarian, a first-of-its-kind blood-based laboratory-developed test (LDT) that uses AI-decoded glycopeptide signatures to assess malignancy risk in women with adnexal masses prior to surgery, performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory. The company also offers collaborative glycoproteomic biomarker discovery and validation services to research partners across oncology, autoimmune, and infectious disease indications.

Product overview

InterVenn Biosciences offers a platform-plus-modules architecture centered on its proprietary GlycoVision AI engine, which automates mass-spectrometry-based glycoproteomic analysis using proprietary neural networks trained on the world's largest clinically annotated glycoproteomic dataset. Layered on top of GlycoVision is the GlycoKnow™ diagnostic franchise — beginning with GlycoKnow™ Ovarian, a CLIA-validated laboratory-developed blood test that uses the platform's AI decoding of glycopeptide signatures to assess malignancy risk in women with adnexal masses — together with collaborative biomarker discovery services that feed new clinical indications and modules (e.g., endometriosis, response-to-ICI, NSCLC, melanoma, RCC, pancreatic, breast, and autoimmune/infectious disease) into the same underlying engine.

Differentiator

Problem solved

Functional benefit

Brands

• GlycoKnow™: A blood-based laboratory-developed test (LDT) that analyzes the glycoproteome to aid in the assessment of adnexal masses for ovarian cancer risk. GlycoKnow™ Ovarian is the lead product in this line.
• GlycoVision

Products and services

• GlycoKnow™ Ovarian A first-of-its-kind AI-driven, blood-based liquid biopsy laboratory-developed test (LDT) that analyzes the glycoproteome to aid clinicians (gynecologic oncologists, women's health specialists) in assessing malignancy risk in women 18+ with a documented adnexal mass prior to surgery. It provides an adjunct likelihood-of-malignancy assessment to inform triage and surgical planning, and is performed in InterVenn's CLIA-certified, CAP-compliant high-complexity clinical laboratory on serum or plasma specimens.
• GlycoVision Proprietary AI-powered platform for high-throughput glycoproteomic analysis that combines advanced mass spectrometry with machine learning algorithms, custom neural networks trained for glycopeptide identification and scoring, and a large clinically annotated glycoproteomic database. It automates and scales biomarker discovery and is the underlying engine on which GlycoKnow™ diagnostic tests and collaborative research services are built; offered to research and biopharma partners as a discovery and validation platform.
• InterVenn Glycoproteomic Biomarker Discovery & Validation Service End-to-end collaborative glycoproteomics service for academic and biopharma research partners, spanning study design, sample processing (serum or plasma), and data analysis/interpretation using the GlycoVision engine. Supports both discovery profiling and targeted approaches, and enables discoveries to be transferred to InterVenn's CLIA lab environment. Applicable across oncology, autoimmune, and infectious disease indications.

Quantifiable outcome

• 17 peer-reviewed publications in glycoproteomics across oncology, autoimmune, and infectious disease
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Society for Immunotherapy of Cancer (SITC)coreGTM or Marketing Partner · 18 May 2026InterVenn is participating in the SITC Annual Meeting in Phoenix, AZ (Nov 4-8, 2026) — a key conference channel for engaging the immuno-oncology community around its immune checkpoint inhibitor biomarker work.
• AransciaflagshipStrategic or Co-development Partner · 7 January 2026Multi-year agreement to accelerate commercialization of the GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test. Aranscia contributes its software suite (Spesana, 2bPrecise, AccessDx Laboratory) and laboratory resources to expand clinical workflows and availability across women's health, oncology, and health system care settings. Aimed at democratizing access to precision diagnostics for ovarian cancer.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Freenome: Multiomics liquid biopsy company developing blood-based colorectal cancer screening and other early-detection assays using AI on proteomic and genomic signals. Comparable to InterVenn's platform-plus-diagnostic architecture using AI/mass spectrometry over blood samples.
• SomaLogic: Proteomics platform company operating SomaScan high-plex protein measurement and developing diagnostic applications. Directly comparable to InterVenn as an AI-driven protein/glycoprotein biomarker discovery platform feeding into clinical diagnostic products.
• GRAIL: Multi-cancer early detection liquid biopsy company pursuing population-scale blood-based screening. Comparable to InterVenn as a blood-based, AI-driven cancer detection platform targeting adnexal mass triage and other early-cancer use cases.
• Natera: Commercial cell-free DNA diagnostics company with oncology and women's health franchises including Signatera and Empower. Comparable to InterVenn's blood-based diagnostic model and its women's-health/oncology go-to-market strategy.
• Oncocyte: Commercial molecular diagnostics company with oncology-focused tests (e.g., DetermaRx, VitaGraft) pursuing reimbursement and clinical adoption. Comparable to InterVenn as a small-cap oncology diagnostics company; Mitch Levine previously served as Oncocyte's CFO before joining InterVenn's board.
• Seer: Proteomics platform company commercializing a nanoparticle-enhanced mass spectrometry workflow for deep, unbiased proteomic profiling. Closely comparable to InterVenn's mass-spectrometry-plus-AI architecture and its claim to a large proprietary annotated dataset feeding biomarker discovery.
• Guardant Health: Leading commercial liquid biopsy company with oncology-focused blood tests for tumor profiling and minimal residual disease. Directly comparable to InterVenn as a blood-based cancer diagnostics franchise pursuing non-invasive oncology workflows through CLIA/CAP lab operations.

Broad incumbents

• Myriad Genetics: Diversified molecular diagnostics company with hereditary cancer, oncology, and women's health franchises. Comparable to InterVenn's clinical cancer diagnostics go-to-market and women's-health positioning; Alec Ford previously led at Myriad before joining InterVenn's board.
• Exact Sciences: Established cancer diagnostics leader (Cologuard, Oncotype DX) pursuing multi-cancer liquid biopsy via the Cancerguard program. A broad incumbent overlapping InterVenn's blood-based, AI-augmented oncology diagnostic ambition and reimbursement strategy.

Emerging players

• BillionToOne: Commercial molecular diagnostics company with a prenatal liquid biopsy franchise (Unity) and an oncology liquid biopsy program (Northstar). Comparable as a private/commercial-stage liquid biopsy company with a women's-health oncology focus similar to GlycoKnow™ Ovarian.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vennbio
• LinkedInlinkedin.com/company/intervenn

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InterVenn